Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Polina Putrik, Sofia Ramiro, Tore K Kvien, Tuulikki Sokka, Till Uhlig, Annelies Boonen, on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group, Merete Lund Hetland

88 Citationer (Scopus)

Abstract

To explore criteria regulating treatment with reimbursed biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) across Europe and to relate criteria to indicators of national socioeconomic welfare.
OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind73
Sider (fra-til)2010-2021
ISSN0003-4967
DOI
StatusUdgivet - 2014

Fingeraftryk

Dyk ned i forskningsemnerne om 'Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?'. Sammen danner de et unikt fingeraftryk.

Citationsformater